Apr 02, 2024 / 01:00PM GMT
Christian Kanstrup - Evaxion Biotech A/S-CEO
Hello, everyone, and a very warm welcome to this Evaxion business update conference call on the back of our full year 2023 results. I'm Christine Kanstrup, I'm the CEO of Evaxion.
With me today, I have Birgitte Rønø, our Chief Scientific Officer; I have Jesper Nyegaard Nissen, our Chief Operating Officer and Chief Financial Officer. What we will be covering today is I will be giving a brief, welcome also a brief corporate update. Then we will have begin, dive into the R&D and business update, and Jesper will be covering the 2023 financial results. After a few conclusion remarks by me, we will be heading in to the Q&A session.
So looking forward to an interactive session, before getting started I just want to direct your attention to the fact that we will be talking about future today. And of course, when talking about the future that entails uncertainty. So I do direct your attention to the forward-looking statement slide, which is contained in the presentation deck for today.
With that,
Q4 2023 Evaxion Biotech A/S Earnings Call (Danish) Transcript
Apr 02, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers